Chris Haqq

2.5k total citations · 1 hit paper
23 papers, 1.9k citations indexed

About

Chris Haqq is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Chris Haqq has authored 23 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Genetics and 5 papers in Oncology. Recurrent topics in Chris Haqq's work include Glioma Diagnosis and Treatment (4 papers), Melanoma and MAPK Pathways (4 papers) and Estrogen and related hormone effects (4 papers). Chris Haqq is often cited by papers focused on Glioma Diagnosis and Treatment (4 papers), Melanoma and MAPK Pathways (4 papers) and Estrogen and related hormone effects (4 papers). Chris Haqq collaborates with scholars based in United States, Canada and Australia. Chris Haqq's co-authors include David G. Ginzinger, Linda Wong, Jessica Bowers, Vita Fedele, Michael Mattie, Christopher C. Benz, Gary K. Scott, Robert Getts, Mika K. Derynck and Daisuke Nonaka and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Chris Haqq

23 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

2006 589 citations Michael Mattie, Christopher C. Benz et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Haqq United States	16	1.2k	640	379	332	304	23	1.9k
A. Jauch Germany	28	1.7k 1.4×	437 0.7×	512 1.4×	169 0.5×	149 0.5×	50	2.6k
J. Keith Killian United States	23	1.1k 0.9×	373 0.6×	266 0.7×	221 0.7×	169 0.6×	44	2.0k
Guido Reifenberger Germany	21	1.1k 0.9×	270 0.4×	443 1.2×	188 0.6×	449 1.5×	26	2.1k
Fréderic Fina France	27	893 0.8×	506 0.8×	687 1.8×	186 0.6×	258 0.8×	87	2.2k
Gunnar Wrobel Germany	19	758 0.6×	287 0.4×	275 0.7×	271 0.8×	114 0.4×	21	1.5k
Nathalie Baeza France	17	1.2k 1.0×	561 0.9×	431 1.1×	128 0.4×	117 0.4×	28	2.2k
Gayatry Mohapatra United States	24	1.2k 1.0×	459 0.7×	410 1.1×	106 0.3×	286 0.9×	34	2.0k
Hiroyuki Momota Japan	19	846 0.7×	357 0.6×	246 0.6×	167 0.5×	233 0.8×	39	1.5k
Joshua M. Francis United States	16	1.5k 1.3×	540 0.8×	454 1.2×	86 0.3×	114 0.4×	26	2.1k
Julie Koeman United States	20	923 0.8×	462 0.7×	365 1.0×	173 0.5×	76 0.3×	26	1.5k

Countries citing papers authored by Chris Haqq

Since Specialization

Citations

This map shows the geographic impact of Chris Haqq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Haqq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Haqq more than expected).

Fields of papers citing papers by Chris Haqq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Haqq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Haqq. The network helps show where Chris Haqq may publish in the future.

Co-authorship network of co-authors of Chris Haqq

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Haqq. A scholar is included among the top collaborators of Chris Haqq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Haqq. Chris Haqq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Semir, David de, Mehdi Nosrati, Vladimir Bezrookove, et al.. (2012). Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proceedings of the National Academy of Sciences. 109(18). 7067–7072. 30 indexed citations

Fizazi, Karim, Johann S. de Bono, Chris Haqq, et al.. (2011). 1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY. European Urology Supplements. 10(2). 338–338. 4 indexed citations

Marbury, Thomas, et al.. (2011). 7057 POSTER A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function. European Journal of Cancer. 47. S502–S502. 3 indexed citations

Kashani–Sabet, Mohammed, Javier Rangel, Sima Torabian, et al.. (2009). A multi-marker assay to distinguish malignant melanomas from benign nevi. Proceedings of the National Academy of Sciences. 106(15). 6268–6272. 76 indexed citations

Torabian, Sima, David de Semir, Mehdi Nosrati, et al.. (2009). Ribozyme-Mediated Targeting of IκBγ Inhibits Melanoma Invasion and Metastasis. American Journal Of Pathology. 174(3). 1009–1016. 8 indexed citations

Kashani–Sabet, Mohammed, Suraj Venna, Mehdi Nosrati, et al.. (2009). A Multimarker Prognostic Assay for Primary Cutaneous Melanoma. Clinical Cancer Research. 15(22). 6987–6992. 56 indexed citations

Danila, Daniel C., Johann S. de Bono, Charles J. Ryan, et al.. (2009). Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). Journal of Clinical Oncology. 27(15_suppl). 5048–5048. 15 indexed citations

Ryan, Charles J., Eleni Efstathiou, Mitchell R. Smith, et al.. (2009). Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. Journal of Clinical Oncology. 27(15_suppl). 5046–5046. 22 indexed citations

Rangel, Javier, Mehdi Nosrati, Stanley P. L. Leong, et al.. (2008). Novel Role for RGS1 in Melanoma Progression. The American Journal of Surgical Pathology. 32(8). 1207–1212. 56 indexed citations

10.

Rubenstein, James L., Jane Fridlyand, Lauren E. Abrey, et al.. (2007). Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma. Journal of Clinical Oncology. 25(11). 1350–1356. 243 indexed citations

11.

Rangel, Javier, Mehdi Nosrati, Sima Torabian, et al.. (2007). Osteopontin as a molecular prognostic marker for melanoma. Cancer. 112(1). 144–150. 83 indexed citations

12.

Mattie, Michael, Christopher C. Benz, Jessica Bowers, et al.. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.. Molecular Cancer. 5(1). 24–24. 589 indexed citations breakdown →

13.

Issa, Samar, Justin H. Hwang, Jon Karch, et al.. (2006). Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. Journal of Clinical Oncology. 24(18_suppl). 7595–7595. 3 indexed citations

14.

Rangel, Javier, Sima Torabian, Ladan Shaikh, et al.. (2006). Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma. Journal of Clinical Oncology. 24(28). 4565–4569. 39 indexed citations

15.

Wang, Jen-Chywan, Mika K. Derynck, Daisuke Nonaka, et al.. (2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proceedings of the National Academy of Sciences. 101(44). 15603–15608. 257 indexed citations

16.

Lawrence, H. Jeffrey, Sheri T. Dorsam, Hideaki Ohta, et al.. (2004). Activation of Stem-Cell Specific Genes by HOXA9 and HOXA10 Homeodomain Proteins in CD34+ Human Cord Blood Cells.. Blood. 104(11). 3227–3227. 4 indexed citations

17.

Rubenstein, James L., Arthur Shen, Jane Fridlyand, et al.. (2004). Additive effect of the combination of 5-aza-2’-deoxycytidine and valproic acid in leukemia cell systems. 64. 1022–1022. 5 indexed citations

18.

Morikawa, Nobuyuki, Trent R. Clarke, Carl D. Novina, et al.. (2000). Human Mullerian-Inhibiting Substance Promoter Contains a Functional TFII-I-Binding Initiator1. Biology of Reproduction. 63(4). 1075–1083. 17 indexed citations

19.

Haqq, Chris, et al.. (1994). Molecular basis of mammalian sexual determination: activation of Mullerian inhibiting substance gene expression by SRY. Science. 266(5190). 1494–1500. 200 indexed citations

20.

Dedhar, Shoukat, Chris Haqq, & Virginia Gray. (1989). Specific Overproduction of Very Late Antigen 1 Integrin in Two Human Neuroblastoma Cell Lines Selected for Resistance to Detachment by an Arg-Gly-Asp-containing Synthetic Peptide. Journal of Biological Chemistry. 264(9). 4832–4836. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact